<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04926818</url>
  </required_header>
  <id_info>
    <org_study_id>CBAF312D2301</org_study_id>
    <nct_id>NCT04926818</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis</brief_title>
  <acronym>NEOS</acronym>
  <official_title>A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients&#xD;
      with multiple sclerosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into a Core Part and Extension Part. The Core Part is a 24-month,&#xD;
      double-blind, triple dummy, randomized, 3-arm active-controlled in children/adolescent&#xD;
      patients aged 10-17 years old with Multiple Sclerosis (MS). The Extension Part is 60-month (5&#xD;
      year) open label (except for first 12 weeks transition which will remain double-blind)&#xD;
      treatment for patients who complete the Core Part of the study and meet all&#xD;
      inclusion/exclusion criteria. The targeted enrollment is 180 participants with multiple&#xD;
      sclerosis which will include at least 5 participants with body weight (BW) ≤40 kg and at&#xD;
      least 5 participants with age 10 to 12 years in each of the ofatumumab and siponimod arms.&#xD;
      There is a minimum 6 month follow up period for all participants (core and extension). Total&#xD;
      duration of the study could be up to 7 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The core part of the study and the first 12 weeks of the extension period (transition) will be double-blinded and the remainder of the extension period will be open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized relapse rate (ARR) in target pediatric participants</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Frequency of relapses assessed by the annualized relapse rate (ARR). The ARR is defined as the average number of confirmed relapses per year (total number of confirmed relapses divided by the total days in the study multiplied by 365.25).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate (ARR) as compared to historical interferon β-1a data</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Frequency of relapses assessed by the annualized relapse rate (ARR) to historical interferon β-1a data. The ARR is defined as the average number of confirmed relapses per year. The historical data for interferon β-1a will derived from prior phase 3 studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized T2 lesion rate</measure>
    <time_frame>Baseline up to 24 months</time_frame>
    <description>Number of new/newly enlarged T2 lesions per year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurofilament light chain (NfL) concentrations</measure>
    <time_frame>Day 1, Months 3,6,12,18,24</time_frame>
    <description>Neurofilament light chain (NfL) concentration in serum of ofatumumab and/or siponimod versus fingolimod</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of ofatumumab</measure>
    <time_frame>Day 1, pre-dose for Day 7, Months 2,3,5,6,12,18,24</time_frame>
    <description>Ofatumumab plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of siponimod</measure>
    <time_frame>Day 1 (2,3,4,6 h), Day 3 (2,3,4,6 h), pre-dose for Months 1 (pre, 3h), 3,5,12</time_frame>
    <description>Siponimod plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of siponimod metabolite (M17)</measure>
    <time_frame>Pre-dose Month 3, 5 and Month 12</time_frame>
    <description>Siponimod metabolite (M17) plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with anti-ofatumumab antibodies</measure>
    <time_frame>Day 1, Pre-Dose Months 2,3,5,6,12,18,24</time_frame>
    <description>Anti-ofatumumab antibodies to demonstrate immunogenicity of ofatumumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and serious adverse events</measure>
    <time_frame>Baseline up approximately 66 months</time_frame>
    <description>Any clinically relevant finding that meets the criteria of an adverse event (as determined by the investigator) identified during the safety assessments (ECG, laboratory and ophthalmological data, pulmonary function tests and vital signs) will be reported as an adverse event</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Multiple Sclerosis (MS)</condition>
  <arm_group>
    <arm_group_label>ofatumumab - 20 mg injection/ placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>siponimod - 0.5 mg, 1 mg or 2 mg/ placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fingolimod - 0.5 mg or 0.25 mg/ placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fingolimod</intervention_name>
    <description>Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).</description>
    <arm_group_label>fingolimod - 0.5 mg or 0.25 mg/ placebo</arm_group_label>
    <other_name>FTY720</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).</description>
    <arm_group_label>ofatumumab - 20 mg injection/ placebo</arm_group_label>
    <other_name>OMB157</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Siponimod</intervention_name>
    <description>Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).</description>
    <arm_group_label>siponimod - 0.5 mg, 1 mg or 2 mg/ placebo</arm_group_label>
    <other_name>BAF312</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fingolimod placebo</intervention_name>
    <description>Fingolimod matching placebo capsule</description>
    <arm_group_label>fingolimod - 0.5 mg or 0.25 mg/ placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Siponimod placebo</intervention_name>
    <description>Siponimod matching placebo tablet</description>
    <arm_group_label>siponimod - 0.5 mg, 1 mg or 2 mg/ placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ofatumumab placebo</intervention_name>
    <description>Ofatumumab matching placebo autoinjector</description>
    <arm_group_label>ofatumumab - 20 mg injection/ placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 10 to &lt;18 years of age (i.e., have not yet had their 18th birthday) at&#xD;
             randomization&#xD;
&#xD;
          2. Diagnosis of multiple sclerosis&#xD;
&#xD;
          3. EDSS score of 0 to 5.5, inclusive&#xD;
&#xD;
          4. At least one MS relapse/attack during the previous year or two MS relapses in the&#xD;
             previous two years prior or evidence of one or more new T2 lesions within 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with progressive MS&#xD;
&#xD;
          2. Participants with an active, chronic disease of the immune system other than MS&#xD;
&#xD;
          3. Participants meeting the definition of ADEM&#xD;
&#xD;
          4. Participants with severe cardiac disease or significant findings on the screening ECG.&#xD;
&#xD;
          5. Participants with severe renal insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80 952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warsaw</city>
        <zip>04 730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsing multiple sclerosis</keyword>
  <keyword>pediatric</keyword>
  <keyword>relapse</keyword>
  <keyword>EDSS</keyword>
  <keyword>ofatumumab</keyword>
  <keyword>siponimod</keyword>
  <keyword>fingolimod</keyword>
  <keyword>RMS</keyword>
  <keyword>MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
    <mesh_term>Siponimod</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

